Secondary Tumors Arising in Patients Undergoing BRAF Inhibitor Therapy Exhibit Increased BRAF–CRAF Heterodimerization
Lise Boussemart(Inserm), Caroline Robert(Institut Gustave Roussy), Julien Adam(Inserm), Christine Mateus(Centre National de la Recherche Scientifique), Margot Rubington(Inserm), Émilie Routier(Université Paris-Saclay), Alexander M.M. Eggermont(University Medical Center Utrecht), Gorana Tomasic, Isabelle Girault(Inserm), Hélène Malka-Mahieu(Université Paris-Sud), Mélanie Laporte(Centre National de la Recherche Scientifique), Marie Breckler(Centre National de la Recherche Scientifique), Nyam Kamsu-Kom(Inserm), Stéphan Vagner(Institut Curie), Andréa Cavalcanti(Institut Gustave Roussy), Sandrine Agoussi(Inserm), Florent Grange(Hôpital Lyon Sud), Ludovic Lacroix(Centre National de la Recherche Scientifique)
Cited by 51
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.8k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Final Version of 2009 AJCC Melanoma Staging and Classification
|Journal of Clinical Oncology|2009|4.6k
Melanoma staging: Evidence‐based changes in the American Joint Committee on Cancer eighth edition cancer staging manual
|CA A Cancer Journal for Clinicians|2017|2.3k